Plain-English translation of NCT06336798 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether pioglitazone, a medication already approved for type 2 diabetes, might help people with pulmonary hypertension due to chronic lung disease. Researchers believe the medication may help improve how cells in the lungs and heart produce energy, which could reduce symptoms and improve outcomes. You would take the medication (or a placebo) for short periods to see how it affects your body's cellular energy production.
Recent research has shown that abnormal energy metabolism in lung and heart cells may drive pulmonary hypertension, and this medication activates a pathway that could restore normal metabolism. This is the first clinical trial to test whether this treatment approach works in people with pulmonary hypertension due to chronic lung disease.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the medication or a placebo first for 28 days, then have a 2-week break, and then receive the other treatment for another 28 days. Throughout the study, you'll attend clinic visits where researchers will measure your cellular energy metabolism and assess how the medication affects your body. The study takes about 3 months total, and you'll need to fast (avoid food) for 6 hours before each visit.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
United States